Drug Eluting Stent (DES)
Drug Eluting Stent, which is put in the coronary artery of patients with aischemic heart disease, is quickly becoming an alternative to a metallic stent.
However, the long-term survival rate for delayed thrombosis has become an international issue.
August 9th 2007,we requested to MHLW and Johnson & Johnson that clinical use of the drug be suspended, because of a basic problem regarding safety and effectiveness, such as proper approval, conditions required for anti-thrombotic medicines which is jointly used, application settings and the replaceability of other treatment methods.
Topics
- YAKUGAI Ombudsperson
- Tie-up Group
No Related Information
